Current progress with serological assays for exotic emerging/re-emerging viruses

Future Virology

Volumn 8, Issue 8, 2013, Pages 745-755

  Mather, Stuart ^a   Scott, Simon ^a   Temperton, Nigel ^a   Wright, Edward ^b   King, Barnabas ^c   Daly, Janet ^c  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

exotic emerging viruses; neutralizing antibodies; pseudotype viruses; serological assays; zoonosis

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; CLIMATE CHANGE; DEFORESTATION; DISEASE RE-EMERGENCE; EPIDEMIC; HUMAN; PRIORITY JOURNAL; REVIEW; RNA VIRUS; SERODIAGNOSIS; TRAVEL; VACCINATION; VIRUS DIAGNOSIS; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 84881420294     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.60     Document Type: Review

References (74)

1. Morse SS. Factors in the emergence of infectious diseases. Emerg. Infect. Dis. 1(1), 7-15 (1995
2. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence.Phil. Trans. R. Soc. Lond. B Biol. Sci. 356(1411), 983-989 (2001
3. Nichol ST, Arikawa J, Kawaoka Y. Emerging viral diseases. Proc. Natl Acad. Sci. USA 97(23), 12411-12412 (2000
4. Epstein JH, Field HE, Luby S, Pulliam JR, Daszak P. Nipah virus: Impact, origins, and causes of emergence. Curr. Infect. Dis. Rep. 8(1), 59-65 (2006
5. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J. The natural history of Hendra and Nipah viruses. Microbes Infect. 3(4), 307-314 (2001
6. Anderson LJ, Baric RS. Emerging human coronaviruses - Disease potential and preparedness. N. Engl. J. Med. 367(19), 1850-1852 (2012
7. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367(19), 1814-1820 (2012
8. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat. Med. 10(12 Suppl.), S70-S76 (2004
9. Becquart P, Wauquier N, Mahlakoiv T et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE 5(2), e9126 (2010
10. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75-109 (2002
11. Ehichioya DU, Hass M, Becker-Ziaja B et al. Current molecular epidemiology of Lassa virus in Nigeria. J. Clin. Microbiol. 49(3), 1157-1161 (2011
12. Suzuki Y, Gojobori T. The origin and evolution of Ebola and Marburg viruses. Mol. Biol. Evol. 14(8), 800-806 (1997
13. Andersen KG, Shylakhter I, Tabrizi S, Grossman SR, Happi CT, Sabeti PC. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Phil. Trans. R. Soc. Lond. B Biol. Sci. 367(1590), 868-877 (2012
14. Gire SK, Stremlau M, Andersen KG et al. Epidemiology. Emerging disease or diagnosis? Science 338(6108), 750-752 (2012
15. Elbers AR, Loeffen WL, Quak S et al. Seroprevalence of Schmallenberg virus antibodies among dairy cattle, The Netherlands, winter 2011-2012. Emerg. Infect. Dis. 18(7), 1065-1071 (2012
16. Mansfield KL, Horton DL, Johnson N et al. Flavivirus-induced antibody cross-reactivity. J. Gen. Virol. 92(Pt 12), 2821-2829 (2011
17. Allwinn R, Doerr HW, Emmerich P, Schmitz H, Preiser W. Cross-reactivity in flavivirus serology: New implications of an old finding? Med. Microbiol. Immunol. 190(4), 199-202 (2002
18. Mascola JR, Louder MK, Winter C et al. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76(10), 4810-4821 (2002
19. Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45(11), 3777-3780 (2007
20. Terletskaia-Ladwig E, Enders G, Meier S, Dietz K, Enders M. Development and evaluation of an automatable focus reduction neutralisation test for the detection of measles virus antibodies using imaging analysis. J. Virol. Methods 178(1-2), 124-128 (2011
21. Monath TP, Gershman M, Staples JE, Barrett ADT. Yellow fever vaccine. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier Saunders, PA, USA, 870-968 (2013
22. Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J. Variation in dengue virus plaque reduction neutralization testing: Systematic review and pooled analysis. BMC Infect. Dis. 12, 233 (2012
23. Mannen K, Ishikawa K, Tachibana J, Mifune K. Methods of increasing the sensitivity of the haemagglutination inhibition test for rabies virus antibody. Bull. World Health Organ. 62(6), 883-892 (1984
24. John TJ, Fulgitini VA. Parainfluenza 2 virus: Increase in hemagglutination titer on treatment with Tween-80 and ether. Proc. Soc. Exp. Biol. Med. 121, 109-111 (1966
25. Boliar S, Stanislawek W, Chambers TM. Inability of kaolin treatment to remove nonspecific inhibitors from equine serum for the hemagglutination inhibition test against equine H7N7 influenza virus. J. Vet. Diagn. Invest. 18(3), 264-267 (2006
26. Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin. Immunother. 9(2), 405-408 (2013
27. Kirkland PD, Delbridge G. Use of a blocking ELISA for antibodies to equine influenza virus as a test to distinguish between naturally infected and vaccinated horses: Proof of concept studies. Aust. Vet. J. 89(Suppl. 1), 45-46 (2011
28. Osterman A, Vizoso-Pinto MG, Jung J et al. A novel indirect immunofluorescence test for the detection of IgG and IgA antibodies for diagnosis of hepatitis E virus infections. J. Virol. Methods 191(1), 48-54 (2013
29. Chan KH, Chan JF, Tse H et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J. Infect. 67(2), 130-140 (2013
30. Khan SA, Dutta P, Khan AM et al. West Nile virus infection, Assam, India. Emerg. Infect.Dis. 17(5), 947-948 (2011
31. Lewthwaite P, Shankar MV, Tio PH et al. Evaluation of two commercially available ELISAs for the diagnosis of Japanese encephalitis applied to field samples. Trop. Med. Int. Health 15(7), 811-818 (2010
32. Anuradha SK, Surekha YA, Sathyanarayan MS et al. Japanese encephalitis virus - common cause of viral encephalitis in paediatric age group in Bellary, Karnataka, India. J. Clin. Diagn. Res. 5(3), 480-482 (2011
33. Roehrig JT, Nash D, Maldin B et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed West Nile virus encephalitis cases. Emerg. Infect. Dis. 9(3), 376-379 (2003
34. Prince HE, Matud JL. Estimation of dengue virus IgM persistence using regression analysis. Clin. Vaccine Immunol. 18(12), 2183-2185 (2011
35. Arroyo J, Miller CA, Catalan J, Monath TP. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol. Med. 7(8), 350-354 (2001
36. Komar N, Langevin S, Monath TP. Use of a surrogate chimeric virus to detect West Nile virus-neutralizing antibodies in avian and equine sera. Clin. Vaccine Immunol. 16(1), 134-135 (2009
37. Nougairede A, De Fabritus L, Aubry F, Gould EA, Holmes EC, de Lamballerie X. Random codon re-encoding induces stable reduction of replicative fitness of Chikungunya virus in primate and mosquito cells. PLoS Pathog. 9(2), e1003172 (2013
38. Pierson TC, Sanchez MD, Puffer BA et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346(1), 53-65 (2006
39. Mattia K, Puffer BA, Williams KL et al. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS ONE 6(11), e27252 (2011
40. Temperton NJ, Wright E. Retroviral Pseudotypes. John Wiley & Sons Ltd, UK (2009
41. Wright E, Hayman DT, Vaughan A et al. Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology 408(2), 183-189 (2010
42. Temperton NJ, Hoschler K, Major D et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi. Viruses 1(3), 105-112 (2007
43. Ferrara F, Molesti E, Bottcher-Friebertshauser E et al. The human transmembrane protease serine 2 is necessary for the production of group 2 influenza A virus pseudotypes. J. Mol. Gen. Med. 7, 309-314 (2012
44. Molesti E, Cattoli G, Ferrara F, Bottcher-Friebertshauser E, Terregino C, Temperton N. The production and development of H7 influenza virus pseudotypes for the study of humoral responses against avian viruses. J. Mol. Gen. Med. 7, 315-320 (2012
45. Scott S, Molesti E, Temperton N, Ferrara F, Bottcher-Friebertshauser E, Daly J. The use of equine influenza pseudotypes for serological screening. J. Mol. Gen. Med. 6, 304-308 (2012
46. Wright E, McNabb S, Goddard T et al. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa. Vaccine 27(51), 7178-7186 (2009
47. Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: A cross-species comparison. J. Gen. Virol. 89(Pt 9), 2204-2213 (2008
48. Kaku Y, Noguchi A, Marsh GA et al. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J. Virol. Methods 160(1-2), 7-13 (2009
49. Tamin A, Harcourt BH, Lo MK et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods 160(1-2), 1-6 (2009
50. Fukushi S, Mizutani T, Saijo M et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS CoV. J. Med. Virol. 78(12), 1509-1512 (2006
51. Temperton NJ, Chan PK, Simmons G et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11(3), 411-416 (2005
52. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol. 74(10), 4933-4937 (2000
53. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: Identification of receptor-deficient cell lines. J. Virol. 72(4), 3155-3160 (1998
54. Ogino M, Ebihara H, Lee BH et al. Use of vesicular stomatitis virus pseudotypes bearing Hantaan or Seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab. Immunol. 10(1), 154-160 (2003
55. Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100(12), 7271-7276 (2003
56. Kolokoltsov AA, Davey RA. Rapid and sensitive detection of retrovirus entry by using a novel luciferase-based content-mixing assay. J. Virol. 78(10), 5124-5132 (2004
57. Kaufmann B, Vogt MR, Goudsmit J et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl Acad. Sci. USA 107(44), 18950-18955 (2010
58. Nelson S, Jost CA, Xu Q et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4(5), e1000060 (2008
59. Hayman DT, Fooks AR, Horton D et al. Antibodies against Lagos bat virus in megachiroptera from West Africa. Emerg. Infect. Dis. 14(6), 926-928 (2008
60. Kuzmin IV, Niezgoda M, Franka R et al. Lagos bat virus in Kenya. J. Clin. Microbiol. 46(4), 1451-1461 (2008
61. Capecchi B, Fasolo A, Alberini I et al. Use of pseudotyoed particles expressing influenza A/VietNam/1194/2004 hemagglutinin in neutralization assays. In: Options for the Control of Influenza VI. International Medical Press Ltd, GA, USA, 303-305 (2007
62. Kaku Y, Noguchi A, Marsh GA et al. Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: Sensitive and high-throughput analysis utilizing secreted alkaline phosphatase. J. Virol. Methods 179(1), 226-232 (2012
63. Desvaux S, Garcia JM, Nguyen TD et al. Evaluation of serological tests for H5N1 avian influenza on field samples from domestic poultry populations in Vietnam: Consequences for surveillance. Vet. Microbiol. 156(3-4), 277-284 (2012
64. Jacobson RH. Validation of serological assays for diagnosis of infectious diseases. Rev. Sci. Tech. 17(2), 469-526 (1998
65. Nefkens I, Garcia JM, Ling CS et al. Hemagglutinin pseudotyped lentiviral particles: Characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol. 39(1), 27-33 (2007
66. Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J. Virol. Methods 165(2), 305-310 (2010
67. Labrosse B, Tourdjman M, Porcher R et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS ONE 5(6), e11036 (2010
68. Mazarakis ND, Azzouz M, Rohll JB et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10(19), 2109-2121 (2001
69. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS CoV) spike glycoprotein-mediated viral entry. Proc. Natl Acad. Sci. USA 101(12), 4240-4245 (2004
70. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197(5), 633-642 (2003
71. Lee HJ, Min KI, Lee J et al. The prM-independent packaging of pseudotyped Japanese encephalitis virus. Virol. J. 6, 115 (2009
72. Ma M, Kersten DB, Kamrud KI, Wool-Lewis RJ, Schmaljohn C, Gonzalez-Scarano F. Murine leukemia virus pseudotypes of La Crosse and Hantaan bunyaviruses: A system for analysis of cell tropism. Virus Res. 64(1), 23-32 (1999
73. Salvador B, Zhou Y, Michault A, Muench MO, Simmons G. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393(1), 33-41 (2009
74. Sharkey CM, North CL, Kuhn RJ, Sanders DA. Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J. Virol. 75(6), 2653-2659 (2001